pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
arch-oncology PRESS RELEASE ARCHIVE
Nov 9, 2020
Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020
Oct 26, 2020
Arch Oncology to Present at Upcoming Conferences
Oct 5, 2020
Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1/2 Trial in Solid Tumors
Jun 22, 2020
Arch Oncology Announces Formation of Scientific Advisory Board
Apr 21, 2020
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors
Aug 12, 2019
Arch Oncology Appoints Drew Dennison to Board of Directors
May 22, 2019
Arch Oncology Appoints Kirk Christoffersen as Chief Business Officer
Mar 29, 2019
Arch Oncology to Present Preclinical Data on Highly-Differentiated Anti-CD47 Antibody AO-176 at the AACR Annual Meeting 2019
Mar 25, 2019
Arch Oncology Raises $50 Million Series B Financing
Feb 6, 2019
Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-Class Profile
